2326-26-3

Basic information

• Product Name: 6alpha,9-difluoro-11beta,21-dihydroxypregna-1,4,16-triene-3,20-dione 21-acetate
• Synonyms: 6alpha,9-difluoro-11beta,21-dihydroxypregna-1,4,16-triene-3,20-dione 21-acetate;6,9-Difluoro-11,21-dihydroxypregna-1,4,16-triene-3,20-dione 21-acetate;6,9-Difluoropregna-1,4,16-triene-11,21-diol-3,20-dione 21-acetate;21-Acetyloxy-6α,9-difluoro-11β-hydroxypregna-1,4,16-triene-3,20-dione;Einecs 219-040-7;6α,9-Difluoro-11β,21-dihydroxy-pregna-1,4,16-triene-3,20-dione
• CAS NO: 2326-26-3
• Molecular Formula: C₂₃H₂₆F₂O₅
• Molecular Weight: 420.4463464
• EINECS: 219-040-7
• Product Categories: Pharmaceuticals, Intermediates & Fine Chemicals, Steroids
• Mol File: 2326-26-3.mol

Chemical Properties

• Melting Point: 209-210 °C
• Boiling Point: 551.8°Cat760mmHg
• Flash Point: 287.5°C
• Appearance: /
• Density: 1.32g/cm³
• Vapor Pressure: 1.77E-14mmHg at 25°C
• Refractive Index: 1.563
• PKA: 12.81±0.70(Predicted)
• CAS DataBase Reference: 6alpha,9-difluoro-11beta,21-dihydroxypregna-1,4,16-triene-3,20-dione 21-acetate(CAS DataBase Reference)
• NIST Chemistry Reference: 6alpha,9-difluoro-11beta,21-dihydroxypregna-1,4,16-triene-3,20-dione 21-acetate(2326-26-3)
• EPA Substance Registry System: 6alpha,9-difluoro-11beta,21-dihydroxypregna-1,4,16-triene-3,20-dione 21-acetate(2326-26-3)

Safety Data

• Hazardous Substances Data: 2326-26-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
6alpha,9-difluoro-11beta,21-dihydroxypregna-1,4,16-triene-3,20-dione 21-acetate is used as an active pharmaceutical ingredient for the preparation of anti-inflammatory and antiallergic agents. Its application is based on its glucocorticoid nature, which allows it to effectively manage inflammation and allergic reactions by modulating the immune system and reducing the production of inflammatory mediators.
Used in Medical Treatments:
6alpha,9-difluoro-11beta,21-dihydroxypregna-1,4,16-triene-3,20-dione 21-acetate is utilized in the treatment of various medical conditions, including rheumatoid arthritis, asthma, and other autoimmune diseases. Its potent anti-inflammatory and immunosuppressive effects make it a valuable asset in managing these conditions and improving the quality of life for patients.
Used in Research and Development:
In addition to its practical applications, 6alpha,9-difluoro-11beta,21-dihydroxypregna-1,4,16-triene-3,20-dione 21-acetate is also used in research and development for the study of steroidal compounds, their mechanisms of action, and potential new therapeutic applications. This helps in the discovery of novel drugs and advancements in the field of medicine.

InChI:InChI=1/C23H26F2O5/c1-12(26)30-11-19(28)15-5-4-14-16-9-18(24)17-8-13(27)6-7-22(17,3)23(16,25)20(29)10-21(14,15)2/h5-8,14,16,18,20,29H,4,9-11H2,1-3H3/t14-,16-,18-,20-,21-,22-,23-/m0/s1

Upstream product

• 72498-89-6 17α, 21-diacetyloxy-9β,11β-epoxy-6α-fluoro-1,4-diene-3,20-dione 
• 3802-45-7 21-acetyloxy-9β,11β-epoxy-6α-fluoro-17α-hydroxy-1,4-diene-3,20-dione 
• 38680-83-0 21-acetyloxy-9β,11β-epoxy-17α-hydroxy-1,4-diene-3,20-dione 
• 4380-55-6 pregna-1,4,9(11)-triene-17α,21-diol-3,20-dione 21-acetate 
• 7753-60-8 anecortave 

Downstream Products

• 4306-83-6 21-acetyloxy-11β,16α,17α-trihydroxy-6α,9α-difluoro-1,4-diene-3,20-dione 
• 356-12-7 fluocinonide 
• 67-73-2 fluocinolone Acetonide 
• 1323943-19-6 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-benzyl-4b,12-difluoro-5-hydroxy-4a,6a-dimethyl-2-oxo-2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-pentaleno[2,1-a]-phenanthrene-6b-carboxylic acid benzylamide 
• 1323943-24-3 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-benzyl-4b,12-difluoro-5-hydroxy-4a,6a-dimethyl-2-oxo-2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-pentaleno[2,1-a]-phenanthrene-6b-carboxylic acid dimethylamide 
• 1323942-39-7 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-(3-chloro-benzyl)-4b,12-difluoro-5-hydroxy-4a,6a-dimethyl-2-oxo-2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-azapentaleno[2,1-a]phenanthrene-6b-carboxylic acid 
• 1323941-12-3 (4aS,4bR,5S,6aS,6bS,9aR,8R,10aS,10bS,12S)-8-(4-Chloro-benzyl)-4b,12-difluoro-5-hydroxy-6b-(2-hydroxy-acetyl)-4a,6a-dimethyl-4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-azapentaleno[2,1-a]phenanthrene-2-one 
• 1323942-09-1 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-benzoyl-4b,12-difluoro-5-hydroxy-6b-(2-hydroxy-acetyl)-4a,6a-dimethyl-4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-azapentaleno[2,1-a]phenanthren-2-one 
• 1323942-29-5 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-5-hydroxy-6b-(2-hydroxy-acetyl)-4a,6a-dimethyl-2-oxo-2,4b,5,6,6a,6b,7,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-azapentaleno[2,1-a]phenanthrene-8-carboxylic acid benzyl ester 
• 1323942-08-0 acetic acid 2-((4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-benzoyl-4b,12-difluoro-5-hydroxy-4a,6a-dimethyl-2-oxo-2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthrene-6b-yl)-2-oxo-ethyl ester 
• 1323942-28-4 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-6b-(2-acetoxy-acetyl)-4b,12-difluoro-5-hydroxy-4a,6a-dimethyl-2-oxo-2,4b,5,6,6a,6b,7,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-azapentaleno[2,1-a]phenanthrene-8-carboxylic acid benzyl ester 
• 1323941-96-3 acetic acid 2-[(4aS,4bR,5S,6aS,6bS,9aR,10aS,12S)-4b,12-difluoro-5-hydroxy-4a,6a-dimethyl-2-oxo-8-(4-(4-hydroxy-phenylsulfanylmethyl)-benzyl)-2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12- tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthrene-6b-yl]-2-oxo-ethyl ester 
• 1421745-63-2 acetic acid 2-[(4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-5-hydroxy-4a,6a-dimethyl-8-(4-methyl-benzyl)-2-oxo-2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthrene-6b-yl]-2-oxo-ethyl ester 
• 1421745-77-8 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-(4-chloro-phenyl)-4b,12-difluoro-5-hydroxy-6b-(2-hydroxy-acetyl)-4a,6a-dimethyl-4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthren-2-one 

Relevant articles and documents

ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF

The invention provides anti-VISTA antibody drug conjugates which may be used for targeted delivery of anti-inflammatory agents such as steroids to immune cells, e.g., myeloid cells. The invention also provides methods of using anti-VISTA antibody drug conjugates in the treatment of inflammatory and/or autoimmune conditions and/or for alleviating the toxicity of anti-inflammatory agents such as steroids.

Improved synthesis of fluocinolone acetonide and process research of 6α,9α-fluorination

An efficient and improved synthetic route of fluocinolone acetonide with combination of bio-fermentation was developed from 21-acetyloxy-17α-hydroxy-4,9(11)-diene-3,20-dione (1a). Process of the 6α and 9α fluorination steps was studied, and it was observe

Novel Pyrrolidine Derivatives of Budesonide as Long Acting Inhaled Corticosteroids for the Treatment of Pulmonary Inflammatory Diseases

Inhaled corticosteroids (ICSs) represent the first line therapy for the treatment of asthma and are also extensively utilized in chronic obstructive pulmonary disease. Our goal was to develop a new ICS with a basic group, which can allow solid state feature modulation, achieving at the same time high local anti-inflammatory effect and low systemic exposure. Through a rational drug design approach, a new series of pyrrolidine derivatives of budesonide was identified. Within the series, several compounds showed nanomolar binding affinity (Ki) with GR that mostly correlated with the effect in inducing GR nuclear translocation in CHO cells and anti-inflammatory effects in macrophagic cell lines. Binding and functional cell-based assays allowed identifying compound 17 as a potent ICS agonist with a PK profile showing an adequate lung retention and low systemic exposure in vivo. Finally, compound 17 proved to be more potent than budesonide in a rat model of acute pulmonary inflammation.

ANTI -INFLAMMATORY STEROIDS CONDENSED IN POSITION 16,17 WITH PYRROLIDINE RING

The present invention relates to novel anti-inflammatory and antiallergic compounds of the glucocorticosteroid series, methods of preparing such compounds, pharmaceutical compositions comprising them, combinations and therapeutic uses thereof. More particularly, the invention relates to glucocorticosteroids that are derivatives of pyrrolidine.

PYRROLIDINE DERIVATIVES

Novel anti-inflammatory and antiallergic compounds of the glucocorticosteroid series according to formulae (I) and (I′) are effective for the prevention and/or treatment of diseases in which the number, activity, and movement of inflammatory cells is implicated.

ISOXAZOLIDINE DERIVATIVES

Anti-inflammatory and antiallergic compounds of the glucocorticosteroid series, according to formula (I) according to formula (I) defined herein are useful for treating diseases of the respiratory tract characterized by airway obstruction.

ISOXAZOLIDINE DERIVATIVES

Anti-inflammatory and antiallergic compounds of the glucocorticosteroid series according to formula (I) defined herein are useful for treating diseases of the respiratory tract characterized by airway obstruction.

ISOXAZOLIDINE DERIVATIVES

The present invention relates to novel anti-inflammatory and antiallergic compounds of the glucocorticosteroid series, methods of preparing such compounds, pharmaceutical compositions comprisingthem, combinations and therapeutic uses thereof. More particularly, the invention relates to glucocorticosteroids that are derivatives of isoxazolidine.

ISOXAZOLIDINE DERIVATIVES

The present invention relates to novel anti-inflammatory and antiallergic compounds of the glucocorticosteroid series, methods of preparing such compounds, pharmaceutical compositions comprising them, combinations and therapeutic uses thereof. More particularly, the invention relates to glucocorticosteroids that are derivatives of isoxazolidine.

ISOXAZOLIDINE DERIVATIVES

The present invention relates to novel anti-inflammatory and antiallergic compounds of the glucocorticosteroid series, methods of preparing such compounds, pharmaceutical compositions comprising them, combinations and therapeutic uses thereof. More particularly, the invention relates to glucocorticosteroids that are derivatives of isoxazolidine.